Gracell's founder explains his company's rationale for BCMA + CD19 in both myeloma and lupus

blonca9
Dec 11, 2023
1 min read

William Cao describes how the same product might be used for cancer and lupus, explains the idea behind FasTCAR manufacturing, and gives his thoughts on the CAR-T market in China.

Recent Posts

See All

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Gracell's founder explains his company's rationale for BCMA + CD19 in both myeloma and lupus

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight